VIM and cancer: Thus, although the well-established antiproliferative action of TGF-β could be monitored in the examined cancer cell models, VIM-AS1 appears to act more selectively and impair primarily pro-tumorigenic responses to TGF-β, such as EMT and cancer cell invasiveness.